Form S-3ASR Kymera Therapeutics,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Kymera Therapeutics (KYMR) PT Raised to $41 at B.Riley
November 1, 2024 5:59 AM EDTB.Riley analyst Kalpit Patel raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $41.00 (from $36.00) while maintaining a Neutral rating.
The analyst comments "Kymera Therapeutics (KYMRNeutral, $41 PT) announced 3Q24 earnings and provided a business update. Patient dosing has commenced for KT-621, the companys STAT6 degrader, with... More
